Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/197709
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Gallus, Silvano | - |
dc.contributor.author | Scala, Marco | - |
dc.contributor.author | Possenti, Irene | - |
dc.contributor.author | Jarach, Carlotta Micaela | - |
dc.contributor.author | Clancy, Luke | - |
dc.contributor.author | Fernandez, Esteve | - |
dc.contributor.author | Gorini, Giuseppe | - |
dc.contributor.author | Carreras, Giulia | - |
dc.contributor.author | Malevolti, Maria Chiara | - |
dc.contributor.author | Commar, Alison | - |
dc.contributor.author | Fayokun, Ranti | - |
dc.contributor.author | Gouda, Hebe N. | - |
dc.contributor.author | Prasad, Vinayak M. | - |
dc.contributor.author | Lugo, Alessandra | - |
dc.date.accessioned | 2023-05-08T13:53:45Z | - |
dc.date.available | 2023-05-08T13:53:45Z | - |
dc.date.issued | 2023-03-08 | - |
dc.identifier.issn | 1600-0617 | - |
dc.identifier.uri | http://hdl.handle.net/2445/197709 | - |
dc.description.abstract | The association between current smoking and coronavirus disease 2019 (COVID-19) progression remains uncertain. We aim to provide up-to-date evidence of the role of cigarette smoking in COVID-19 hospitalisation, severity and mortality. On 23 February 2022 we conducted an umbrella review and a traditional systematic review via PubMed/Medline and Web of Science. We used random-effects meta -analyses to derive pooled odds ratios of COVID-19 outcomes for smokers in cohorts of severe acute respiratory syndrome coronavirus 2 infected individuals or COVID-19 patients. We followed the Meta -analysis of Observational Studies in Epidemiology reporting guidelines. PROSPERO: CRD42020207003. 320 publications were included. The pooled odds ratio for current versus never or nonsmokers was 1.08 (95% CI 0.98-1.19; 37 studies) for hospitalisation, 1.34 (95% CI 1.22-1.48; 124 studies) for severity and 1.32 (95% CI 1.20-1.45; 119 studies) for mortality. Estimates for former versus never-smokers were 1.16 (95% CI 1.03-1.31; 22 studies), 1.41 (95% CI: 1.25-1.59; 44 studies) and 1.46 (95% CI 1.31-1.62; 44 studies), respectively. Estimates for ever-versus never-smokers were 1.16 (95% CI 1.05-1.27; 33 studies), 1.44 (95% CI 1.31-1.58; 110 studies) and 1.39 (95% CI 1.29-1.50; 109 studies), respectively. We found a 30-50% excess risk of COVID-19 progression for current and former smokers compared with never -smokers. Preventing serious COVID-19 outcomes, including death, seems the newest compelling argument against smoking. | - |
dc.format.extent | 12 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | European Respiratory Society (ERS) | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1183/16000617.0191-2022 | - |
dc.relation.ispartof | European Respiratory Review, 2023, vol. 32, num. 167 | - |
dc.relation.uri | https://doi.org/10.1183/16000617.0191-2022 | - |
dc.rights | cc by-nc (c) Gallus, Silvano et al, 2023 | - |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/3.0/es/ | * |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | COVID-19 | - |
dc.subject.classification | Hàbit de fumar | - |
dc.subject.other | COVID-19 | - |
dc.subject.other | Smoking | - |
dc.title | The role of smoking in COVID-19 progression: a comprehensive meta-analysis | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2023-04-21T12:23:08Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 36889786 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
220191.full.pdf | 801.98 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License